Introduction
Signaling through epidermal growth factor (EGF) receptors (ErbB receptors) is important for fundamental cellular functions, such as proliferation, migration, growth and differentiation 1 . In human biology, ErbB signaling is involved in normal growth and development, as well as in the initiation and progression of disease. Based on the aberrant expression in a variety of malignant tumors, ErbB family members have been recognized as targets in anti-cancer therapy, and are now used in the treatment of breast and colon malignancies.
Besides tumor biology, ErbB signaling is critically involved in renal electrolyte homeostasis.
Moreover, ErbB family members are implicated in the development of end organ damage, as occurs in hypertension 2 and atherosclerosis 3 . Therefore, the therapeutic potential of targeting ErbB receptors and ErbB signaling pathways may go beyond the field of oncology. In this review, we report on the physiological and disease-related aspects of renal ErbB signaling, with attention to potential benefits and downsides of systemic ErbB inhibition in the healthy and diseased kidney.
ErbB receptors: upstream and downstream signaling
The ErbB receptor family belongs to subclass I of the receptor tyrosine kinase (RTK) superfamily, incorporating epidermal growth factor receptor (EGFR) (HER1 (ErbB1)), HER2/neu (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). All ErbB receptors have a common extracellular ligand-binding site, a single membrane-spanning region, and a cytoplasmic protein tyrosine kinase domain 1 .
Upon ligand binding, ErbB receptors undergo conformational changes that induce the formation of receptor homo-or heterodimers. As a consequence, the intrinsic tyrosine kinase domain is activated, phosphorylating specific tyrosine residues within the cytoplasmic tail of the receptor.
These autophosphorylated residues serve as docking sites for signaling molecules, whose recruitment activates intracellular signaling pathways. Individual ErbB receptors are able to discriminate between binding ligands, and phosphorylation of different tyrosine residues occurs upon binding of different ligands to the same ErbB receptor 4 . Moreover, receptors are ligandselective, and differing receptor dimers can be formed. As such, a variety of downstream signal transduction pathways can be selectively activated.
Thus far, 11 ligands for ErbB receptors have been identified. Epidermal growth factor (EGF), transforming growth factor-! (TGF-!), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin, epigen and epiregulin preferentially bind to the EGFR, whereas neuregulin (NRG) family ligands (NRG-1, NRG-2, NRG-3 and NRG-4) bind to ErbB3 and ErbB4 but not to the EGFR (Figure 1 ). ErbB2 is unique in the family, since it has no known ligand but forms a heterodimer with other ErbB receptors. As a stabilized complex, it can then induce downstream signaling. ErbB3 lacks intrinsic kinase activity, but can be phosphorylated by other ErbB receptors upon heterodimerisation 3 . It is important to note that all ErbB ligands exist as inactive transmembrane precursors, requiring proteolytic cleavage of their ectodomain in order to be released as mature soluble ligands. This cleavage is performed by ADAM (a disintegrin and metalloprotease) family members. ADAM9, 10, 12, 15, 17 and 19 have been demonstrated to 44 cleave ErbB ligands 5 , thereby regulating ErbB ligand availability. ADAM-dependent EGFR ligandshedding can be induced by factors that bind G-protein coupled receptors (GPCRs), such as angiotensin II binding the AT1 receptor (AT1R). Therefore, GPCR-induced, ADAM-assisted EGFR activation has been termed transactivation 6 . Depending on the tissue, different ADAMs may be involved, as ADAM17 was implicated in angiotensin II-induced EGFR transactivation in the kidney 7 , and ADAM12 in the heart 8 . At present, it is not fully elucidated how GPCRs activate
ADAMs. It has been demonstrated that Gq and second messengers, such as Ca2+ and reactive oxygen species (ROS), are required for angiotensin II-induced, ADAM17-dependent, HB-EGF shedding in EGFR transactivation 9 . Additionally, GPCR binding was shown to alter ADAM17 activity by modulating its phosphorylation status through ERK via Thr735 phosphorylation 10 . 47
Physiology -Renal organogenesis
ErbB family members are crucially involved in nephrogenesis. EGFR knockout mice suffer from impaired epithelial development in several organs, including the kidney, and die at mid-gestation or shortly after birth 11 . In human nephrogenesis, the EGFR was detected in collecting ducts in both early and late gestational stages 12;13 , while ErbB2 was expressed in proximal tubules and collecting ducts 13 . ErbB4 was only reported in the ureteric bud and developing tubules of embryonic rat kidneys 14 . EGF and TGF-! were prominently expressed during both early and late nephrogenesis, with strong expression in developing tubules and glomeruli 12;15 . Interestingly, AR was expressed in developing glomeruli only around 18 weeks of gestation 16 . Figure 3 provides an overview of ErbB family member expression during human nephrogenesis.
In vitro models advocate a role for ErbB signaling in nephrogenesis. Recombinant EGF and TGF-! stimulate growth of cultured embryonic kidney cells 17 , while epiregulin and AR enhance ureteric bud branching morphogenesis 18 . In vitro inhibition of EGFR tyrosine kinase activity or TGF-! reduced cell tubulogenesis and ureteric bud development 19;20 . Interestingly, AT1R binding by angiotensin II induced ureteric bud branching in vitro, a processes that depended on EGFR phosphorylation 21 . Unfortunately, none of the in vitro studies provided insight into the exact functional mechanism through which ErbB signaling influences nephrogenesis. EGF and TGF-! were expressed in structures that develop into the Bowman's capsule, proximal tubules, distal tubules and collecting ducts, and AR was detected in podocytes. ErbB2 was expressed in developing proximal tubules and the collecting ducts, and the EGFR in collecting ducts only.
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Physiology -Electrolyte homeostasis
Ligand-dependent EGFR signaling has diverse roles in human renal physiology. EGF modulates glomerular hemodynamics and renal metabolism 22 , while TGF-! was crucial for survival of renal medullary cells during osmotic stress 23 . HB-EGF determined tubular transepithelial resistance (TER) by adjusting the configuration of tight junction proteins in tubules 24 , a general mechanism to manage the settings for paracellular ion conductance. Moreover, EGF could specifically control sodium reabsorption across distal nephron epithelia by adjusting epithelial sodium channel (ENaC) activity 25 ( Figure 4) . It was recently shown that EGF-mediated stimulation of TRPM6 occurs via signaling through Src kinases and Rac1, thereby redistributing endomembrane TRPM6 to the plasma membrane 32 . The functional existence of this reabsorption mechanism was supported by a cohort study of 98 colorectal cancer patients who were treated with anti-EGFR monoclonal antibodies, as most patients developed hypomagnesemia resulting from renal Mg 2+ wasting 33 . Based on the 49 abundance of EGFR and its ligands in tubular epithelial cells, it is conceivable that EGFR signaling is involved in the homeostasis of other electrolytes as well. In this light, ADAMs also come into sight, as EGFR signaling depends on activity of these sheddases in cleaving inactive EGFR ligand precursors from the cell membrane. Corroboratively, ADAM19 34 and ADAM17
(unpublished observations) have been shown to be highly expressed in distal tubular epithelial cells of healthy human kidneys. 
Renal disease
Tissue distribution of ErbB family members
Constitutive EGFR expression was detected in glomeruli, tubules and interstitium of most normal human kidneys 35 , and EGFR upregulation was noted in various forms of glomerulonephritis and in allograft nephropathy 36;37 . In the latter, marked EGFR expression was found in glomerular fibrotic lesions, and tubular EGFR correlated with the extent of interstitial fibrosis. HB-EGF was strongly expressed in the glomerular mesangium of patients with glomerulonephritis, but absent in normal kidneys. Moreover, mesangial HB-EGF correlated with the extent of mesangial proliferation, and cultured mesangial cells that were exposed to recombinant HB-EGF proliferated and synthesized collagen types I and III 38 . TGF-! and the EGFR were strongly expressed in primitive tubules in human kidney dysplasia 39 and in cyst epithelial cells of patients with autosomal dominant polycystic kidney disease (ADPKD) 40 .
Contrary to the expression pattern of HB-EGF, TGF-! and the EGFR, EGF was strongly expressed in the RPTCs and DCTs of normal kidneys, while it was absent in RPTCs in reflux nephropathy. Furthermore, decreased tubulointerstitial EGF expression correlated with severity of apoptosis 41 . In line with these findings, an increase in EGF mRNA was strongly associated with a decrease in tubulointerstitial apoptosis in chronic renal disease, while EGF decrease was associated with a decrease in renal function 42 . To date, the human renal tissue expression of AR, betacellulin, epigen and epiregulin has not been investigated. It must be remarked that although the local availability of EGFR ligands modulates EGFR signaling, the expression of these ligands as assessed by immunohistochemistry could reflect both cellular production and cellular uptake.
The dissociating tissue expression profile of the EGFR and its ligands in normal versus diseased human kidneys, together with the observed correlations with parameters of fibrosis, suggests that EGFR signaling is implicated in the pathophysiology of renal fibrosis. Interestingly, EGFR ligands are inversely regulated, suggesting different functions for ligands that bind the same receptor.
Experimental interventions in ErbB signaling
Genetic and pharmacological ErbB targeting has provided functional insight into the versatile role of ErbB signaling in the kidney. Transgenic mice that carry a kidney tubule-specific dominant negative EGFR isoform function normally under basal conditions, yet display reduced tubular dilatation following subtotal nephrectomy and reduced tubular atrophy, interstitial fibrosis and mononuclear cell infiltration after induction of renal ischemia 43 . In rats with nitric oxide deficiencyinduced hypertension, treatment with an EGFR tyrosine kinase inhibitor prevented the development of renal vascular and glomerular fibrosis and the decline in renal function 44 . This protective response was associated with normalized downstream MAPK activity and reduced collagen I expression. Diabetic rats that received an EGFR tyrosine kinase inhibitor showed a reduction in tubular epithelial cell proliferation, glomerular enlargement and kidney weight 45 .
Waved-2 (wa-2) mice, expressing a point mutation in the EGFR that reduces receptor tyrosine kinase activity by >90%, have normally developed kidneys. However, when the wa-2 mutation was introduced into the murine orpk mutation model of autosomal recessive polycystic kidney disease (ARPKD), a substantial decrease in cyst formation and improvement of renal function was observed 46 . Also treatment with an EGFR tyrosine kinase inhibitor could reduce cyst formation and prevent renal function decline. This effect was more profound when EGFR signaling inhibition was combined with ADAM17 inhibition, expectedly due to decreased EGFR ligand availability 47 . Interestingly, also ErbB2 inhibition resulted in reduced renal cyst development, and cultured ADPKD cells showed reduced migration following EGFR or ErbB2 inhibition 48 .
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Altogether, constitutive ErbB signaling is needed for normal development, and inhibition of ErbB activity is beneficial in experimental renal fibrotic and cystogenic disorders. Nevertheless, a certain basal level of ErbB activity seems needed to recover from harmful insults, as wa-2 mice with HgCl2-induced acute nephrotoxicity had more severe tubular injury with a concomitant decrease in recovery of renal function when compared to their wildtype littermates 49 . Therefore, ErbB signaling may initially serve processes of tissue repair, but may lead to excess tissue fibrosis and functional deterioration under overcompensating reparative actions. It needs yet to be determined whether these experimental observations also apply for human ErbB signaling.
Transactivation of the EGFR in renal disease and hypertension
Angiotensin II has a well-recognized role in the development of renal fibrotic lesions. Historically, most of its effects have been attributed to hemodynamic regulation and indeed, renal fibrotic lesions can be identified in most hypertensive patients. Only recently, it was discovered that angiotensin II can also induce EGFR transactivation via AT1R-induced ADAM-dependent shedding of membrane-bound EGFR ligands. EGFR transactivation occurs in various kidney cell types and in vascular smooth muscle cells (VSMCs) 50 . In the latter, EGFR transactivation induced cell hypertrophy and migration, which plays a role in the development of vascular lesions as can be seen in atherosclerosis and hypertension. In rat glomerular afferent arterioles, EGFR signaling contributed to intracellular calcium influx, which is part of the contractile response to angiotensin II 51 . Moreover, GPCR-induced EGFR transactivation promoted vasoconstriction both in vitro and in vivo 2 , and angiotensin II-induced hypertension in rats was attenuated by treatment with EGFR antisense nucleotides 52 . Furthermore, leptin-induced hypertension 53 and monocrotaline-induced pulmonary hypertension 54 were reduced by pharmacological EGFR tyrosine kinase inhibitors, while endothelin-induced hypertension was attenuated in wa-2 mice 55 . In rats transgenic for human renin and angiotensinogen (dTGR hypertensive rats), blood pressure and associated renal and cardiac tissue damage could be reduced by pharmacological inhibition of MAPK p38, an important signal molecule downstream the EGFR 56 .
In the kidney, wildtype mice developed severe renal fibrotic lesions after infusion of angiotensin II, both on glomerular and interstitial level, whereas mice expressing a kidney tubule-specific dominant negative isoform of the EGFR were protected from these lesions 7 . Additionally, it was shown that TGF-! knockout mice, as well as mice that were treated with a pharmacological ADAM17 inhibitor, were protected from angiotensin II-induced renal lesions. 52
ErbB signaling in mechanisms of renal repair
Although interventional studies have provided convincing evidence for a detrimental role of ErbB signaling in renal disease, ErbB activity is also implicated in the underlying processes of renal repair. In RPCTs, EGF 59 , HB-EGF 60 and epiregulin 61 can activate the EGFR and induce regenerative proliferation and migration. EGFR activation via AR or HB-EGF was prerequisite for induction of full RPTC motility 62 and HB-EGF, AR and epiregulin induced proliferation of cultured mesangial cells 63 .
In vivo, HB-EGF enhances renal tubular cell regeneration and repair after renal ischemia 64 .
Moreover, EGFR activation by HB-EGF protected kidney cells from apoptosis in a cell-cell or cellmatrix deprived environment, indicating that HB-EGF has cytoprotective effects 65 . In rat unilateral ureteral obstruction (UUO), EGF expression was decreased when compared with normal kidneys.
Administration of EGF during acute tubular injury and following relief of UUO attenuated tubular damage and accelerated tubular regeneration 66 . Additionally, subcutaneous injection of EGF or TGF-! increased the recovery of renal epithelial cells 67 . While folic acid-induced acute renal injury caused an increase in expression of the EGFR, HB-EGF and TGF-!, EGF was completely depressed 68 . The consequences of EGF signaling could be species-dependent, as EGF administration during hydronephrosis potentiated renal cell death in mice, but cell survival in rats 69 .
ErbB signaling: beneficial or detrimental to the kidney?
Signaling through ErbB receptors serves bidirectional outcomes. ErbB signaling was proposed as an unfavourable mechanism in the development of renal disease when upregulated ErbB family member expression was identified in fibrotic conditions. Interventional animal models supported These data further confirm that physiologic ErbB signaling is needed for renal electrolyte homeostasis and maintenance of kidney integrity, illustrating that systemic ErbB targeting is likely to come at a price. In this respect, the discovery that different intracellular tyrosine kinases are phosphorylated upon binding of different ligands to the same ErbB receptor is crucial. As such, rather than inhibiting all ErbB signaling pathways, selectively targeting individual signaling cascades comes into view. A clinical example used in renal transplantation is the immunosuppressive agent rapamycin, which inhibits signaling molecule m-TOR (mammalian target of rapamycin) downstream of ErbB receptors. Alternatively, beneficial ErbB signaling pathways could be selectively activated, thereby appreciating the versatile role of ErbB signaling.
Finally, based on the widespread functions of ErbB signaling in human biology, the development of strategies to traffic ErbB inhibitors to specific sites is of great importance. Based on the ongoing efforts to unravel the precise mechanism of ErbB signaling, mainly driven by the cancer research community, it is expected that the best days of ErbB targeting are yet to come.
